- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03272113
SKIP-IT Smoking Cessation in Pregnancy (SKIP-IT)
Promoting Smoking Cessation During Pregnancy: a Combined Feasibility and Pilot Trial of a Theory-based Intervention Using Narrative, Images and Embedded Behaviour Change Techniques, Delivered Via Text-messaging
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Smoking during pregnancy carries serious risks to mother and infant health. More babies whose mothers smoke are stillborn or die within the first year of life. Smoking during pregnancy results in increased rates of intrauterine growth retardation, preterm birth, and babies' longer-term risk of developing heart disease and diabetes. Pregnant women who smoke are more likely to experience miscarriage, placental abruption, pregnancy-induced hypertension and later conditions such as lung cancer and heart disease.
Reduction in smoking in pregnancy has been a long standing health policy target however there is limited evidence of effectiveness of many smoking cessation interventions and their uptake is generally low. We have developed, and carried out initial testing of an intervention to support smoking cessation in pregnant women using narrative, story-telling delivered via automated text-messages. The intervention aims to alter women's perceptions of risk, social norms, outcomes and self-efficacy using three key elements. 1. a narrative story of a fictional young pregnant woman 'Megan' trying to stop smoking by overcoming a series of commonplace barriers. 2) images showing the size of their fetus and its stage of development 3) an interactive 'help' function to receive a supportive, tailored response. Behaviour change techniques for smoking cessation in pregnancy are embedded in the intervention.
A randomised controlled trial is required to test the effectiveness of the intervention in reducing smoking in pregnancy. The aim of this study is to investigate the feasibility and likelihood of success of the narrative and image-based intervention for smoking cessation in pregnant women. If successful the intervention will be tested in a full-scale (Phase III) multi centre randomised controlled trial.
Objectives:
- To assess acceptability and willingness to be randomised to the narrative and image based intervention or usual care.
- To assess and compare the feasibility of recruitment strategies, the level of participants' retention in the study and engagement with the intervention.
- To assess the acceptability and likely impact of the intervention among pregnant smokers.
- To estimate the required sample size for a full trial.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Ayr, Verenigd Koninkrijk
- NHS Ayrshire and Arran
-
Perth, Verenigd Koninkrijk
- NHS Tayside
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Women 16 years of age or over,
- Live within the catchment areas of study sites,
- Up to and including 14 weeks of pregnancy,
- Current smoker,
- Own or regularly use a mobile phone with media capability,
- Understand written English,
- Able to give informed consent.
Exclusion Criteria:
- Women who do not currently smoke,
- Live outside the catchment areas of study sites,
- Over 14 weeks of pregnancy,
- Do not use or have access to a mobile phone with media capability,
- Cannot understand written English,
- Not able to give informed consent,
- Already enrolled in an alternative formal smoking cessation trial at the time of referral to the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Control
Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support. Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week. |
|
|
Experimenteel: Intervention
Women will receive usual care as described above plus the SKIP-IT intervention
|
A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recruitment rate
Tijdsspanne: 23 months
|
Progression to a full trial will require recruitment ≥50% of women who give permission to have their details passed to the research team (i.e.
those who express initial interest in the study).
|
23 months
|
|
Drop out rate
Tijdsspanne: 23 months
|
Progression to a full trial will require <30% dropout
|
23 months
|
|
Direction of effect
Tijdsspanne: 23 months
|
Progression to a full trial will require direction of effect on smoking cessation rate in favour of the intervention.
|
23 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Engagement
Tijdsspanne: 23 months
|
Engagement in the intervention will be assessed using data captured by the computer system which monitors the text message responses.
|
23 months
|
|
Acceptability
Tijdsspanne: 23 months
|
Acceptability of the intervention will be assessed in short interviews conducted with intervention group participants at the follow-up points
|
23 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Smoking cessation outcomes
Tijdsspanne: At each subsequent data collection time-point (4 weeks post-randomisation, 36 weeks of pregnancy, 6-7 weeks post due-date, 12-13 weeks post due-date)
|
|
At each subsequent data collection time-point (4 weeks post-randomisation, 36 weeks of pregnancy, 6-7 weeks post due-date, 12-13 weeks post due-date)
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- RMS2119
- HIPS/16/4 (Ander subsidie-/financieringsnummer: Scottish Government Chief Scientist Office)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Stoppen met roken
-
Boston UniversityFlight Attendant Medical Research InstituteVoltooid
-
Cedars-Sinai Medical CenterUniversity of California, San FranciscoVoltooidTweedehands smoking | Vasculaire verouderingVerenigde Staten
-
Peking Union Medical College HospitalRun Shaw Hospital, Zhejiang University School of Medicine; Hangzhou Medisol Technology...Nog niet aan het wervenTweedehands smoking | Passief roken | Verontreiniging door tabaksrookChina
-
Mustafa Kemal UniversityOnbekendTweedehands smokingKalkoen
Klinische onderzoeken op SKIP-IT
-
University of WashingtonNational Institute of Nursing Research (NINR)VoltooidAstma | Slaap stoornisVerenigde Staten
-
University of Texas at AustinBaylor College of Medicine; University of Kansas Medical CenterVoltooid
-
Philips Clinical & Medical Affairs GlobalVoltooidPerifere slagaderziekte | Kritieke ischemie van ledematenOostenrijk
-
Oslo University HospitalCentre for Appearance Research, University of the West of England, UKAanmelden op uitnodigingBrandwonden | Gespleten lip en gehemelte | Craniofaciale afwijkingen | Huid conditie | Andere omstandigheden die leiden tot een zichtbaar verschilNoorwegen
-
ShireVoltooidHunter-syndroomVerenigde Staten, Verenigd Koninkrijk
-
Integro TheranosticsVoltooidBorstkanker | DCIS | Invasief kanaalcarcinoom van de borstVerenigde Staten
-
Liverpool School of Tropical MedicineKenya Medical Research Institute; LVCT HealthWervingZwangerschap | Gezondheidssystemen | Elektronische gezondheidsinformatiesystemen voor de gemeenschap | Opname in de prenatale kliniekKenia
-
ShireVoltooidHunter-syndroomSpanje, Verenigde Staten, Canada, Verenigd Koninkrijk, Frankrijk, Australië, Mexico
-
Benjamin Van Voorhees, MD, MPHNorthwestern University; NorthShore University HealthSystem; Advocate Health Care; Harvard Vanguard Medical Associates en andere medewerkersVoltooidGrote Depressie | Depressieve afleveringenVerenigde Staten
-
Mary LacyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Voltooid